期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗霉菌性阴道病三种中药复方体外对白色念珠菌生物膜形成的影响 被引量：7

下载PDF
导出
摘要 目的观察3种中药复方体外对白色念珠菌生物膜形成的影响。方法采用结晶紫染色法和MTT法评价白色念珠菌生物膜的体外生长动力学,微量稀释法检测3种中药复方对白色念珠菌悬浮菌及其生物膜的抑制作用以及药物包被对白色念珠菌生物膜形成作用。结果生物膜内白色念珠菌数量随培养时间延长而增加。3种中药复方对白色念珠菌悬浮菌的最低抑菌浓度50%(MIC50)分别为3.255,3.565,3.875mg/ml,对生物膜的SMIC50与SMIC80分别是3.255,6.51,3.565,7.12mg/ml,3.875,7.623mg/ml。3种中药复方包被浓度分别在7.882,3.808,6.357mg/ml以上时对其生物膜形成的抑制作用有显著性。结论 3种中药复方对体外白色念珠菌生物膜具有明显的抑制作用。
作者 官妍 汪长中 沈非 吴泓 王艳 云云
机构地区 安徽中医学院.中西医结合临床学院
出处 《时珍国医国药》 CAS CSCD 北大核心 2010年第5期1176-1177,共2页 Lishizhen Medicine and Materia Medica Research
基金 安徽省高校自然科学研究项目(No.KJ2008B223)
关键词 中药复方 白色念珠菌 生物膜
分类号 R285.5 [医药卫生—中药学]
  • 相关文献

参考文献11

  • 1倪慕云,贾仲华,王宏杰.抗白色念珠菌中草药筛选概况[J].中西医结合杂志,1991,11(7):443-444. 被引量：6
  • 2汪长中,程惠娟,官妍,汪本凡,王艳,汤华阳,乐红霞,宋功道.黄连解毒汤对体外白念珠菌生物膜形成的影响[J].热带病与寄生虫学,2007,5(2):82-84. 被引量：21
  • 3谢舜辉,谢义达,曾宪稆,丁让览.中药内服外用治疗白色念珠菌性阴道炎33例[J].上海中医药杂志,1996,30(4):34-35. 被引量：11
  • 4Ramage JW,Walle KV,Wickes BL,et al.Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms[J].Antimicrob Agents Chemother,2001,45(9):2475.
  • 5孙秋宁,方凯.念珠菌生物膜的结构、影响因素及其对抗真菌药的敏感性[J].中国医学科学院学报,2002,24(4):385-388. 被引量：10
  • 6Xiaogang Li,Zhun Yan,Jianping Xu.Quantitative variation of biofilms among strains in natural populations of Candida albicans[J].Microbiology,2003,49:353.
  • 7National Committee for Clinical Laboratory Standards,1997.Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:approved standard.NCCLS document M27-A.National Committee for Clinical Laboratory Standards,Wayne,Pa.
  • 8Hawesr S P,Douglas L G,.Biofilm formation by Candida species on the surface of catheter materials in vitro[J].Infection and Immunity,1994,2:915.
  • 9Stefano P Bachmann,Kacy VandeWalle,Gordon Ramage,et al.In Vitro Activity of Caspofungin against Candida albicans Biofilms[J].Antimicrob Agents,2002,46:3591.
  • 10M Henriques,J Azeredo,R Oliveira.Candida albicans and Candida dubliniensis:comparision of biofilm formation in terms of biomass and activity[J].British Journal of Biomedical Science,2006,63(1):5.

二级参考文献13

  • 1[1]Wey SB, Mori MA. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med, 1988, 148:2642-2645
  • 2[2]Nguyen MH, Peacock Jr JE. Therapeutic approaches in patients with candidemia:evaluation in a muliticenter, propective, observational study. Arch Intern, 1995, 155:2429-2435
  • 3[3]Odds FC. Candida infections: an overview. Crit Rev Nicrobiol, 1987, 15:1-5
  • 4[4]Crump JA, Colllgnon PJ. Intravascular catheter-assocated infections. Eur J Clin Microbiol Infect Dis, 2000, 19:1-8
  • 5[5]Baillie GS, Douglas LJ. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol, 1999, 310:644-656
  • 6[6]Costerton JW, Stewart PS. Bacterial biofilms: a common cause of persistent infections. Science, 1999, 284:1318-1322
  • 7[7]Ramage GW, Walle KV, Wickes BL, et al. Standa-dized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemcther,2001, 45:2475-2479
  • 8[8]Hawser SP, Norris H, Jessup C J, et al. Comparison of a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl) -5- (phenylamino)carbonyl-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol,1998, 36:1450-1452
  • 9[9]National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast's approved standard. NCCLS Document. M27-A. Wayne, PA (USA) : National Committee for Clinical Laboratory Standards. 1997
  • 10[10]Kuhn DM, Chandra J, Mukher PK, et al. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Imm, 2002, 70:878-888

共引文献41

同被引文献157

引证文献7

二级引证文献36

时珍国医国药
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部